Abstract:Background: Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2) is a critical glycolytic regulator responsible for upregulation of glycolysis in response to insulin and adrenergic signaling. PFKFB2, the cardiac isoform of PFK-2, is degraded in the heart in the absence of insulin signaling, contributing to diabetes-induced cardiac metabolic inflexibility. However, previous studies have not examined how the loss of PFKFB2 affects global cardiac metabolism and function. Methods: To address this, we have generated a mouse model with a cardiomyocyte-specific knockout of PFKFB2 (cKO). Using 9-month-old cKO and control (CON) mice, we characterized impacts of PFKFB2 on cardiac metabolism, function, and electrophysiology. Results: cKO mice have a shortened lifespan of 9 months. Metabolically, cKO mice are characterized by increased glycolytic enzyme abundance and pyruvate dehydrogenase (PDH) activity, as well as decreased mitochondrial abundance and beta oxidation, suggesting a shift toward glucose metabolism. This was supported by a decrease in the ratio of palmitoyl carnitine to pyruvate-dependent mitochondrial respiration in cKO relative to CON animals. Metabolomic, proteomic, and western blot data support the activation of ancillary glucose metabolism, including pentose phosphate and hexosamine biosynthesis pathways. Physiologically, cKO animals exhibited impaired systolic function and left ventricular (LV) dilation, represented by reduced fractional shortening and increased LV internal diameter, respectively. This was accompanied by electrophysiological alterations including increased QT interval and other metrics of delayed ventricular conduction. Conclusions: Loss of PFKFB2 results in metabolic remodeling marked by cardiac ancillary pathway activation. This could delineate an underpinning of pathologic changes to mechanical and electrical function in the heart. Clinical perspective: What is New?: We have generated a novel cardiomyocyte-specific knockout model of PFKFB2, the cardiac isoform of the primary glycolytic regulator Phosphofructokinase-2 (cKO).The cKO model demonstrates that loss of cardiac PFKFB2 drives metabolic reprogramming and shunting of glucose metabolites to ancillary metabolic pathways.The loss of cardiac PFKFB2 promotes electrophysiological and functional remodeling in the cKO heart.What are the Clinical Implications?: PFKFB2 is degraded in the absence of insulin signaling, making its loss particularly relevant to diabetes and the pathophysiology of diabetic cardiomyopathy.Changes which we observe in the cKO model are consistent with those often observed in diabetes and heart failure of other etiologies.Defining PFKFB2 loss as a driver of cardiac pathogenesis identifies it as a target for future investigation and potential therapeutic intervention.

Dysfunctional β-cell longevity in diabetes relies on energy conservation and positive epistasis

Heterogeneous Development of Β-Cell Populations in Diabetes-Resistant and Susceptible Mice

Glycolysis Inhibition Induces Functional and Metabolic Exhaustion of CD4+ T Cells in Type 1 Diabetes

Unique features of β‐cell metabolism are lost in type 2 diabetes

Intracellular lipid metabolism impairs β cell compensation during diet-induced obesity.

Metabolic and functional specialisations of the pancreatic beta cell: gene disallowance, mitochondrial metabolism and intercellular connectivity

175-OR: the Mitochondrial Life Cycle Determines SS-Cell Maturity Through Activation of the Integrated Stress Response

Metabolic Stress and Compromised Identity of Pancreatic Beta Cells

Loss of cardiac PFKFB2 drives Metabolic, Functional, and Electrophysiological Remodeling in the Heart

E2F1 transcription factor mediates a link between fat and islets to promote β cell proliferation in response to acute insulin resistance

Sel1L-Hrd1 ER-associated degradation maintains β cell identity via TGF-β signaling

1769-P: Single-Nucleus Multiomics Reveals Unique Molecular Signatures of ß-Cell Heterogeneity and Compensation in Human Obesity

375-OR: Epigenetic Control of Beta-Cell Stress Response and Senescence

187-OR: Declines in ß-Cell Glucose Responsiveness Correlate with Loss of Glucose Metabolism during T1D Pathogenesis

Characterization of Signaling Pathways Associated with Pancreatic β-cell Adaptive Flexibility in Compensation of Obesity-linked Diabetes in db/db Mice

339-OR: Enhanced Expression of Zinc Finger Protein 385D Leads to Type 2 Diabetes Phenotype in Human Beta Cells

The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation

LONP1 regulation of mitochondrial protein folding provides insight into beta cell failure in type 2 diabetes

Yy1 Depletion in Pancreatic Beta Cells Leads to Energy Source Switch from Glycolysis to Oxidative Phosphorylation

Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes